Uni-Bio Science Group Partners with Kexing Biopharm to Expand Osteoporosis Treatment Bogutai® to Six International Markets
核心洞察
Uni-Bio Science Group (搜索) has granted Kexing Biopharm (搜索) exclusive commercialization rights for Bogutai® (搜索) (Teriparatide Injection) in six international markets including Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico.
Bogutai® (搜索) demonstrated remarkable commercial success in China with 248.9% year-on-year revenue growth in the first half of 2025, reaching approximately HK$65.6 million since its March 2024 launch.
The partnership targets a nearly USD 1.5 billion osteoporosis market in the cooperation regions, with over 10 million patients, and expects revenue generation as early as end of 2026.
Uni-Bio Science Group (搜索) has announced a strategic partnership with Kexing Biopharm (搜索) to accelerate the global expansion of its osteoporosis treatment Bogutai® (搜索) (Teriparatide Injection). Under the landmark agreement signed in September 2025, Beijing Genetech Pharmaceutical (搜索) Co., Ltd., a subsidiary of Uni-Bio Science Group, has granted Kexing Biopharm exclusive rights to commercialize Bogutai® in six international markets: Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico.
The partnership represents a significant milestone for both companies, with Bogutai® (搜索) expected to complete registration and generate revenue in these cooperation regions as early as the end of 2026. The osteoporosis market in these target regions is estimated at nearly USD 1.5 billion, with a patient population exceeding 10 million.
Strong Commercial Performance Drives International Expansion
Bogutai® (搜索) has demonstrated exceptional market adoption since its launch in China in March 2024. The recombinant human parathyroid hormone analog (PTH1–34) achieved remarkable revenue growth of 248.9% year-on-year in the first half of 2025, reaching approximately HK$65.6 million. This impressive performance underscores the strong demand for innovative osteoporosis therapies and highlights the untapped potential in global markets.
The drug is specifically indicated for postmenopausal women with osteoporosis who are at high risk of fractures. Unlike traditional antiresorptive therapies that primarily inhibit bone resorption, Bogutai® (搜索) functions as an anabolic treatment that actively stimulates osteoblast activity, promotes new bone formation, and increases bone mineral density through enhanced bone remodeling.
Addressing Critical Unmet Medical Need
Osteoporosis affects over 200 million people globally, with the aging population exacerbating its prevalence. The condition, often referred to as a "silent killer," is typically asymptomatic in early stages, leading to delayed diagnoses and severe complications such as fractures. Treatment rates remain alarmingly low worldwide – in China, only 6.5% of individuals receive osteoporosis treatment within six months of a fracture. Similarly, emerging markets across the Middle East and North Africa face low diagnosis and treatment rates despite growing awareness and significant patient populations.
Injectable therapies like Teriparatide have been recommended by the Guidelines for Rational Drug Use of Osteoporosis in Primary Care (2021) for patients unable to tolerate oral medications, those with poor adherence, or individuals at high risk of fractures, including elderly patients with multiple vertebral or hip fractures.
Strategic Partnership Leverages Complementary Strengths
The collaboration brings together Uni-Bio Science Group (搜索)'s innovative therapeutic development capabilities with Kexing Biopharm (搜索)'s extensive international commercialization expertise. Kexing Biopharm has over 20 years of international commercialization experience and has built a strong marketing network spanning the European Union and emerging markets, with established subsidiaries and offices that have achieved market access and sales in dozens of countries including Brazil, Philippines, and Indonesia.
"Teriparatide Injection is a transformative therapy with immense potential in overseas markets," said Mr. Kingsley Leung, Chairman of Uni-Bio Science Group (搜索). "By partnering with Kexing Biopharm (搜索), a company with a robust international commercialization network and proven operational expertise, we are confident in our ability to bring Bogutai® (搜索) to patients in need across key regions."
Mr. Zhao Yanqing, General Manager of Kexing Biopharm (搜索), added: "We are excited to join forces with Uni-Bio Science Group (搜索) to unlock the regional potential of Bogutai® (搜索). With our established capabilities in regulatory approvals and market promotion, we aim to accelerate product registration and commercialization, ensuring that this innovative therapy reaches patients quickly and effectively."
Comprehensive Osteoporosis Treatment Portfolio
The addition of Bogutai® (搜索) to Kexing Biopharm (搜索)'s portfolio complements its existing success with denosumab injection, creating a comprehensive suite of osteoporosis treatments that combines "anti-resorptive" and "bone-forming" therapies. This synergy enhances the competitiveness of both companies in addressing the growing global demand for osteoporosis care.
Broader International Strategy and Pipeline Development
Beyond this partnership, Uni-Bio Science Group (搜索) is actively pursuing FDA approval for Bogutai® (搜索) in the United States, having already received a waiver for in vivo bioequivalence studies. With this expedited regulatory pathway, FDA approval is anticipated in 2027, further solidifying the Group's position as a leader in osteoporosis treatment.
The Group is also advancing innovative pipeline products, including Uni-PTH (microneedle) for osteoporosis and UB107 (搜索) (a Class III medical device) for bone repair, reinforcing its commitment to addressing unmet medical needs in bone metabolism and regenerative medicine.
Bogutai® (搜索) represents the active 34-amino-acid N-terminal region of the full 84-amino-acid human parathyroid hormone and has been widely recognized for its efficacy and safety. The drug is recommended by numerous domestic and international clinical guidelines and is particularly effective in improving bone microarchitecture and reducing fracture risk in postmenopausal women at high risk of fractures.